Evaluation of antiviral treatment for hepatitis B with tenofovir and entecavir at the viral hepatitis outpatient clinic of the tropical medicine research center in Rondônia / Avaliação do tratamento antiviral da hepatite B com tenofovir e entecavir no ambulatório de hepatites virais do centro de pesquisa em medicina tropical de Rondônia
The emergence of treatment-resistant strains has been an obstacle in antiviral treatment of hepatitis B, which is carried out when the disease evolves to the chronic phase. In 2017, the Ministry of Health limited the therapeutic arsenal to the use of Tenofovir and Entecavir, due to their greater eff...
| Autores: | , , , , , , , |
|---|---|
| Tipo de documento: | artigo |
| Estado: | Versão publicada |
| Data de publicação: | 2021 |
| País: | Brasil |
| Recursos: | Instituto Superior de Educação Vera Cruz (VeraCruz) |
| Repositório: | Revista Veras |
| Idioma: | português |
| OAI Identifier: | oai:ojs2.ojs.brazilianjournals.com.br:article/39100 |
| Acesso em linha: | https://ojs.brazilianjournals.com.br/ojs/index.php/BRJD/article/view/39100 |
| Access Level: | Acceso aberto |
| Palavra-chave: | hepatitis B treatment Tenofovir Entecavir. |
| Resumo: | The emergence of treatment-resistant strains has been an obstacle in antiviral treatment of hepatitis B, which is carried out when the disease evolves to the chronic phase. In 2017, the Ministry of Health limited the therapeutic arsenal to the use of Tenofovir and Entecavir, due to their greater effectiveness and genetic barrier. However, there are no comparative studies of the antiviral activity of these two drugs in the state of Rondônia; such studies would improve the treatment of this disease. Thus, the objective of this study is to evaluate the therapeutic response of hepatitis B patients treated with Entecavir and Tenofovir at state of Rondônia. Patient data were analyzed in medical records containing information about the treatment used and the evolution of each patient’s clinical condition. The tests observed are those that detect HBV DNA to assess viral load, HBV serological markers and liver transaminases, to monitor the evolution of the disease. As a result, the samplings and correlations carried out in this study indicated that the efficacy of both Entecavir and Tenofovir was satisfactory in view of the different profiles of chronic HBV patients evaluated, since they reduced the viral load and normalized transaminases. The data obtained may help to understand the profile and therapeutic response of patients infected with the HBV virus who are treated with Tenofovir and Entecavir, as well as to disseminate pharmacoepidemiological data. |
|---|